Clovis price target raised to $104 from $94 at Leerink Leerink raised its price target for Clovis shares to $104 calling the stock a top pick for 2014. The firm sees multiple pipeline catalysts for Clovis and keeps an Outperform rating on the stock.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Foundation Medicine and Clovis Oncology partner for cancer diagnostic Foundation Medicine (FMI) and Clovis Oncology (CLVS) are expanding their ongoing collaboration to incorporate a coordinated regulatory strategy for the development of a novel Premarket Approval companion diagnostic test. This test is designed for use by physicians to identify patients most likely to respond to rucaparib, Clovis’ poly polymerase inhibitor currently the subject of Phase 2 and Phase 3 clinical trials in patients with ovarian cancer. This companion diagnostic is being developed in parallel with the clinical development of rucaparib to facilitate an FDA submission of the PMA for the companion diagnostic concurrent with the New Drug Application for rucaparib.